{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&_page=0&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "items" : [{"_about" : "http://data.parliament.uk/resources/1507827", "AnsweringBody" : [{"_value" : "Women and Equalities"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1507827/answer", "answerText" : {"_value" : "<p>The Minister for Equalities\u2019 role represents all aspects of the women and equalities portfolio in Cabinet. This portfolio has not changed. The Cabinet role will be supported by the Minister for Women and the equalities Lords Minister.<\/p><p>The regular Women and Equalities Questions session in the Commons also retains that name, to reflect its scope including women\u2019s issues. Details of Ministerial priorities will be shared in due course.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2022-10-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-10-12T09:32:11.62Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "31"}
      , "answeringDeptShortName" : {"_value" : "Women and Equalities"}
      , "answeringDeptSortName" : {"_value" : "Women and Equalities"}
      , "date" : {"_value" : "2022-09-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Women and Equalities: Departmental Responsibilities"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Minister for Women and Equalities, if he will make an assessment of the potential impact of the change in ministerial title from Minister for Women and Equalities to Minister for Equalities on (a) the scope of his ministerial brief, (b) his ministerial objectives and (c) future Government policy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "55113"}
    , {"_about" : "http://data.parliament.uk/resources/1314113", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1314113/answer", "answerText" : {"_value" : "<p>The Vaccine Taskforce brought onboard specialist communications support as contingent labour using the Public Sector Resourcing framework, rather than signing a contract with Admiral as a company. This contingent labour ceased involvement with the Vaccine Taskforce at the end of 2020.<\/p><p> <\/p><p>Details of commercial arrangements with all firms and contract labour used by the Vaccine Taskforce have been published in line with the usual transparency arrangements.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-05-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-05-17T13:46:48.807Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-05-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the Answer of 11 March 2021 to Question 164467 on Coronavirus: Vaccination, how much Admiral has been paid to date for communications services; and what the total value is of the contract with Admiral.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "714"}
    , {"_about" : "http://data.parliament.uk/resources/1301511", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1301511/answer", "answerText" : {"_value" : "<p>In order to maximise the economic and environmental opportunities of the transition to zero emission vehicles, the UK Government is supporting the creation of a circular economy for electric vehicle batteries.<\/p><p> <\/p><p>This includes supporting the innovation, infrastructure, and regulatory environment for a UK battery recycling industry, including reuse in second life applications (such as energy storage) and development of efficient recycling techniques to extract maximum value.<\/p><p> <\/p><p>The Government has allocated £318m to the Faraday Battery Challenge which is playing a leading role in promoting the reuse and recycling of battery components. The Faraday Institution\u2019s £10 million \u2018ReLib\u2019 (Reuse and Recycling of Lithium-ion Batteries) research project is developing the technological, economic and legal infrastructure to allow high percentages of the materials in lithium-ion batteries at the end of their first life to be reused or recycled.<\/p><p> <\/p><p>The Automotive Transformation Fund has been designed to support strategic investments in the electric vehicle supply chain, the scope of which includes battery recycling facilities.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-18T17:21:40.08Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-03-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Batteries: Recycling"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 26 February 2021 to Question 153244 on Electric Vehicles: Production, what steps he is taking to support and grow the UK's lithium battery recycling capabilities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "166410"}
    , {"_about" : "http://data.parliament.uk/resources/1300104", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1300104/answer", "answerText" : {"_value" : "<p>The Government has provided funding to establish Centres of Excellence for vaccines to expand the UK\u2019s manufacturing capacity and associated advanced therapeutics. The aim is to respond to this pandemic as well as increase the UK\u2019s pandemic preparedness for the future.<\/p><p> <\/p><p>Investments which will contribute to our future preparedness include:<\/p><p> <\/p><ul><li>£93 million to accelerate the completion and expanded capacity of the Vaccines Manufacturing Innovation Centre in Oxfordshire;<\/li><\/ul><p> <\/p><ul><li>£127 million for the Cell and Gene Therapy Catapult in Braintree, Essex;<\/li><\/ul><p> <\/p><ul><li>£8.6 million for the Centre of Process Innovation (CPI) to develop Good Manufacturing Process (GMP)-ready messenger RNA (mRNA) manufacturing capability;<\/li><\/ul><p> <\/p><ul><li>As recently announced in the Budget, a further £5 million for the CPI to support their creation of a \u201clibrary\u201d of mRNA vaccines developed to tackle emerging COVID-19 variants;<\/li><\/ul><p> <\/p><ul><li>Funding for the expansion of the Valneva factory in Livingston, Scotland; and<\/li><\/ul><p> <\/p><ul><li>£4.7 million for skills training through the Advanced Therapies Skills Training Network which will ensure that the UK has the skills and expertise to operate existing and upcoming facilities.<\/li><\/ul>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-16T15:09:50.72Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-03-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 12 February 2021 to Question 148771, on Vaccines: Manufacturing Industries, what steps he has taken to increase offline vaccine manufacturing infrastructure since the beginning of the covid-19 outbreak.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "164460"}
    , {"_about" : "http://data.parliament.uk/resources/1300117", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1300117/answer", "answerText" : {"_value" : "<p>Early in the existence of the Vaccine Taskforce, public communication on vaccines was identified as a key challenge for the successful delivery of COVID-19 vaccines. The Government strengthened its communication function to support this significant undertaking and communication specialists sourced by Admiral (with experience in clinical trials and of working with the National Institute for Health Research (NIHR)) were brought onboard using the Public Sector Resourcing framework.<\/p><p> <\/p><p>The communication specialists sourced by Admiral worked with the NIHR to develop the world\u2019s first national citizen registry so that individuals could sign up to participate in clinical vaccine trials. As a result, over 454,000 people have signed up to date.<\/p><p> <\/p><p>Admiral was also involved in creating a proactive communications programme aimed at encouraging greater sign-up to the registry through the \u201cCOVID-19: the search for a vaccine\u201d podcast. This provided a factual transparent source of information on vaccines for UK citizens, combating the anti-vaccination movement, and highlighting the UK's role as a leader in vaccine research and development. The podcast included an episode that specifically covered the need to include people from the Black, Asian and ethnic minority communities in trials and addressed some of the concerns within these communities.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-11T16:53:43.89Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-03-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what work Admiral Associates has undertaken with the Vaccine Taskforce on helping to ensure that covid-19 vaccines are taken up by hard to reach groups.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "164467"}
    , {"_about" : "http://data.parliament.uk/resources/1299384", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1299384/answer", "answerText" : {"_value" : "<p>The UK was the first country in the world to procure, authorise, and start a vaccination programme using the Pfizer/BioNTech and Oxford/AstraZeneca vaccines. The Government has secured access to 457 million doses, across eight different vaccine developers. As of 11 March, over 22.8 million individuals have been vaccinated with a first dose in the UK.<\/p><p> <\/p><p>At the Spending Review 2020, the Government announced it had made available more than £6 billion in total to develop, manufacture, and procure COVID-19 vaccines. Of that, we confirmed £733 million in 2021-22 to purchase successful vaccines and £128 million for research and development (R&amp;D) and vaccines manufacturing. Further funding will be allocated from the COVID-19 reserve as needed.<\/p><p> <\/p><p>For R&amp;D, we have invested:<\/p><ul><li>£33.6 million for the Human Challenge Programme.<\/li><li>£20 million to the University of Oxford to fund clinical trials for its COVID-19 vaccine.<\/li><li>Over £40 million to Imperial College London for the development of its vaccine.<\/li><\/ul><p> <\/p><p>At Budget 2021, the Government announced funding of:<\/p><ul><li>£28 million to increase the UK\u2019s capacity for vaccine testing, support for clinical trials, and to improve the UK\u2019s ability to rapidly acquire samples of new variants of COVID-19.<\/li><li>£22 million for a world-leading study to test the effectiveness of combinations of different COVID-19 vaccines. This will also fund the world\u2019s first study assessing the effectiveness of a third dose of vaccine to improve the response against current and future variants of COVID-19.<\/li><li>A further £5 million on top of a previous £9 million investment in clinical-scale mRNA manufacturing, to create a \u2018library\u2019 of vaccines that will work against COVID-19 variants for possible rapid response deployment.<\/li><\/ul><p> <\/p><p>For manufacturing, the Government has invested over £300 million to secure and scale-up the UK\u2019s manufacturing capabilities to be able to respond to the pandemic. This includes:<\/p><p>a) Facilities that have come online:<\/p><ul><li>£4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres.<\/li><li>£8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire.<\/li><li>£65.5 million for the early manufacture of the Oxford/AstraZeneca vaccine.<\/li><li>Funding for fill and finish capabilities through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the Oxford/AstraZeneca vaccine.<\/li><\/ul><p>b) Facilities that will come online later this year, to help provide longer-term UK capacity:<\/p><ul><li>£93 million to accelerate the completion and expanded role of the Vaccines Manufacturing Innovation Centre in Oxfordshire.<\/li><li>£127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.<\/li><\/ul><p>In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-12T08:49:25.18Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-03-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what proportion of the £6 billion of additional funding for vaccine development and procurement announced in Budget 2021 will be spent on (a) research and development, (b) manufacturing and (c) procurement; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "162590"}
    , {"_about" : "http://data.parliament.uk/resources/1299386", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1299386/answer", "answerText" : {"_value" : "<p>The UK was the first country in the world to procure, authorise, and start a vaccination programme using the Pfizer/BioNTech and Oxford/AstraZeneca vaccines. The Government has secured access to 457 million doses, across eight different vaccine developers. As of 8 March, over 22.2 million individuals have been vaccinated with a first dose.<\/p><p>At the Comprehensive Spending Review 2020, the Government announced it has made available more than £6 billion in total to develop, manufacture, and procure COVID-19 vaccines. Of that, £733 million in 2021-22 was confirmed to purchase successful vaccines and £128 million was confirmed for the research and development (R&amp;D) of vaccines, as well as their manufacture. Further funding may be allocated from COVID-19 reserves as needed.<\/p><p>On R&amp;D, we have allocated:<\/p><ul><li>£33.6 million for the Human Challenge Programme.<\/li><li>£20 million to the University of Oxford to fund clinical trials for their COVID-19 vaccine.<\/li><li>Over £40 million to Imperial College London for the development of their vaccine.<\/li><\/ul><p>At Budget 2021, the Government announced funding of:<\/p><ul><li>£28 million to increase the UK\u2019s capacity for vaccine testing, support for clinical trials, and to improve the UK\u2019s ability to rapidly acquire samples of new variants of COVID-19.<\/li><li>£22 million for a world-leading study to test the effectiveness of combinations of different COVID-19 vaccines. This will also fund the world\u2019s first study assessing the effectiveness of a third dose of vaccine to improve the response against current and future variants of COVID-19.<\/li><li>A further £5 million on top of a previous £9 million investment in clinical-scale mRNA manufacturing, to create a \u2018library\u2019 of vaccines that will work against COVID-19 variants for possible rapid response deployment.<\/li><\/ul><p>On manufacturing,the Government has invested over £300 million to secure and scale-up the UK\u2019s manufacturing capabilities to be able to respond to the pandemic. This includes:<\/p><p>a) Facilities that have come online:<\/p><ul><li>£4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres.<\/li><li>£8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire.<\/li><li>£65.5 million for the early manufacture of the Oxford/AstraZeneca vaccine.<\/li><li>Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales, which is currently providing fill and finish capabilities to the Oxford/AstraZeneca vaccine.<\/li><\/ul><p>b) Facilities that will come online later this year, to help provide longer-term UK capacity:<\/p><ul><li>£93 million to accelerate the completion and expanded role of the Vaccines Manufacturing Innovation Centre in Oxfordshire.<\/li><li>£127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.<\/li><\/ul><p>In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-08", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-08T16:27:24.177Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-03-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, how much funding from the public purse has been spent on covid-19 vaccine (a) manufacturing and (b) research and development since 1 March 2020; if he will make a comparative assessment of the adequacy of that funding spent since 1 March 2020 and the £128 million ringfenced for covid-19 vaccine R&D and manufacturing in Budget 2021; and what proportion of that funding ringfenced in Budget 2021 the Government plans to spend on covid-19 vaccine (i) manufacturing (ii) research and development.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "162591"}
    , {"_about" : "http://data.parliament.uk/resources/1293452", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1293452/answer", "answerText" : {"_value" : "<p>Data is not collected on vaccinations delivered by occupation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-16T15:22:43.217Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-03-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, by what date all teaching staff will have been vaccinated for covid-19 in England; and how many and proportion of those staff will have been vaccinated by 8 March 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "160650"}
    , {"_about" : "http://data.parliament.uk/resources/1288935", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1288935/answer", "answerText" : {"_value" : "<p>The Government has committed to invest £200 million towards a dedicated Life Sciences Investment Programme, to enable the most exciting life sciences companies to scale and grow in the UK.<\/p><p>When the programme is launched by the British Business Bank it will leverage around £400 million of private sector investment, making around £600 million of financing available to the sector over the next 10 years.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-03-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-01T15:54:30.593Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-02-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Science: Finance"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, how much sciences investment was provided by the British Business Banks life sciences investment programme in 2020; and what the projected spend of that programme is in 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "157104"}
    , {"_about" : "http://data.parliament.uk/resources/1287711", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287711/answer", "answerText" : {"_value" : "<p>The World Health Organisation declared a coronavirus pandemic on 11 March 2020 and we would expect it in due course to declare a move to a post-pandemic period, as it has done previously for the H1N1 influenza pandemic in 2010.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-02-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-24T16:29:42.077Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the contract with AstraZeneca for at cost vaccine for the duration of the covid-19 pandemic, how the end of the pandemic is defined.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "155032"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-06-18&_page=1&tablingMemberConstituency=Newcastle+upon+Tyne+Central&answer.answeringMemberConstituency=Stratford-on-Avon", "page" : 0, "startIndex" : 1, "totalResults" : 44, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}